News

Multimedia

Conferences

Publications

Brand Insights

Resources

Sustainability
DE&I
Pandemic
Finance
Legal
Technology
Regulatory
Global
Pricing
Strategy
R&D/Clinical Trials
Opinion
Executive Roundtable
Sales & Marketing
Executive Profiles
Leadership
Market Access
Patient Engagement
Supply Chain
Industry Trends

Eversana Reveals New Portfolio of Consulting Services

February 11, 2020

Article

Pharmaceutical Executive

Eversana, an independent provider of commercial services to the life sciences industry, revealed Eversana Consulting, its new global consulting services focused on the pharma and biotech industries. Eversana Consulting was created to address challenges across the product lifecycle.

Related Content

Report: Obesity Drug Market Estimated to be Worth $200 Billion by 2031

Don Tracy, Associate Editor

September 11th 2024

Article

A recent study by Morningstar predicts that 16 new weight-loss drugs could be on the market by 2029.

Beyond the Birthrate: The Societal Costs of Maternal Mortality

Miranda Schmalfuhs

September 6th 2024

Podcast

Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.

Pharma Pulse 9/11/24: 2024 Veeva R&D and Quality Summit Coverage, Oracle’s Missteps in Cloud Computing & more

Miranda Schmalfuhs

September 11th 2024

Article

The latest news for pharma industry insiders.

Empty Shelves, Urgent Solutions

Miranda Schmalfuhs

August 5th 2024

Podcast

Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts, alternative solutions to ensure continued access to medications for all Americans, potential long term consequences if these pharmacy closures continue, and more

Zongertinib Demonstrates High Objective Response Rate in Previously Treated Advanced Non-Small Cell Lung Cancer

Don Tracy, Associate Editor

September 10th 2024

Article

Results from the Phase Ib Beamion LUNG-1 trial found that zongertinib achieved an objective response rate of 66.7% in previously treated patients with advanced non-small cell lung cancer with HER2 mutations.